Vermillion, Inc. (NASDAQ:VRML)’s stock price shot up 6.6% during trading on Thursday . The stock traded as high as $0.76 and last traded at $0.65, 12,587 shares traded hands during mid-day trading. A decline of 96% from the average session volume of 336,176 shares. The stock had previously closed at $0.61.

The company’s 50 day simple moving average is $0.53 and its 200 day simple moving average is $0.79. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.91.

Several large investors have recently bought and sold shares of the business. Perkins Capital Management Inc. acquired a new position in shares of Vermillion in the third quarter worth $176,000. CVI Holdings LLC acquired a new position in shares of Vermillion in the second quarter worth $71,000. Vanguard Group Inc. grew its stake in shares of Vermillion by 145.8% in the second quarter. Vanguard Group Inc. now owns 1,984,250 shares of the company’s stock worth $1,766,000 after acquiring an additional 1,177,152 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in shares of Vermillion in the second quarter worth $278,000. Finally, Calamos Advisors LLC acquired a new position in shares of Vermillion in the second quarter worth $712,000. Institutional investors and hedge funds own 24.17% of the company’s stock.

Vermillion Company Profile (NASDAQ:VRML)

Vermillion, Inc, together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women.

Featured Article: Technical Analysis of Stocks and What It Means

Receive News & Ratings for Vermillion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion and related companies with MarketBeat.com's FREE daily email newsletter.